Considering your experience with Sharlife so far, how likely are you to recommend us to a friend or colleague?
Not at all likelyExtremely likely
(Optional)
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
9989Health technology
$2.3B
Market Cap
Shariah Analysis
Failed
Business
Cash
Liabilities
Based on AAOIFI screening standards, Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H appears to be Failed.
Business Activity
Revenue breakdown data currently unavailable.
Financial Screening
FYE 2024
Cash (<30%)51.03%
Non-Shariah Cash Items
Cash And Cash Equivalents$1.7B
Other Short Term Investments$868.4M
Liabilities (<30%)59.41%
Non-Shariah Liabilities
Long Term Debt$1.1B
Long Term Capital Lease Obligation$57.8M
Current Debt$1.8B
Market Data
Exchange
HKEX
CurrencyUSD
CountryHong Kong
Last Updated2025-12-15
Disclaimer: Shariah screening is based on the latest available financial data. Market conditions and company activities may change. Always conduct your own due diligence.
HKEX
